# EDGAR Filing Document

**Accession Number:** 0000839087
**File Stem:** 0001213900-25-112966
**Filing Date:** 2025-11
**Character Count:** 8984
**Document Hash:** 0237d8c89ac17fbd1604bbed65213cf2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-112966.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001213900-25-112966

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251119

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VASO Corp
- **CENTRAL INDEX KEY:** 0000839087
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112871434
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-18105
- **FILM NUMBER:** 251501984

**BUSINESS ADDRESS:**
- **STREET 1:** 137 COMMERCIAL STREET, STE. 200
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803
- **BUSINESS PHONE:** 516-997-4600

**MAIL ADDRESS:**
- **STREET 1:** 137 COMMERCIAL STREET, STE. 200
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VASOMEDICAL, INC
- **DATE OF NAME CHANGE:** 20120606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VASOMEDICAL INC
- **DATE OF NAME CHANGE:** 19950517

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FUTURE MEDICAL PRODUCTS INC /DE/
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): <u>November 19, 2025</u>

**VASO CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| Delaware | 0-18105 | 11-2871434 |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(I.R.S. Employer<br> Identification No.)** |

---

---

| |
|:---|
| 137 Commercial St., Suite 200, Plainview, New York 11803 |
| **(Address of Principal Executive Offices and Zip Code)** |

---

---

| |
|:---|
| (516) 997-4600 |
| **Registrant's Telephone Number, Including Area Code** |

---

---

| |
|:---|
| Not Applicable |
| **(Former Name or Former Address, if Changed Since Last Report)** |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of Each Class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of Each Exchange on which Registered** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Exchange Act (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01.** Other Events

On November 19, 2025, Vaso Corporation announced its agreement to sell its wholly-owned subsidiary, VasoHealthcare IT Corp. A press release announcing the transaction is attached as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 [November 19, 2025 Press Release](ea026653501ex99-1_vaso.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 20, 2025

---

| | |
|:---|:---|
| **VASO CORPORATION** | **VASO CORPORATION** |
| By: | /s/ Jun Ma |
| Name: | Jun Ma |
| Title: | Chief Executive Officer and President |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

Vaso Corporation Announces Divestiture of Subsidiary

**Vaso Corporation**<br> 137 Commercial Street<br> Plainview, New York 11803<br> Tel: (516) 997-4600 Fax: (516) 997-2299

**Investor Contact:**<br> Jonathan Newton<br> Investor Relations<br> Phone: 516-997-4600

Email: jnewton@vasocorporation.com

**PLAINVIEW, N.Y, Nov. 19, 2025 (GLOBE NEWSWIRE) --** Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, announced today that it had reached an agreement, subject to certain conditions, with Nano-X Imaging Ltd. ("Nanox") (Nasdaq: NNOX), an innovative medical imaging technology company, to sell one of its subsidiaries, VasoHealthcare IT Corp. The parties intend to complete the sale within a couple of weeks.

VasoHealthcare IT Corp. ("VasoHealthcare IT"), a healthcare IT application value added reseller, is a division of Vaso's information technology business segment. "The decision to sell our VasoHealthcare IT subsidiary to Nanox resulted from a strategic review of our lines of business," Dr. Jun Ma, President and Chief Executive Officer of Vaso, commented on the transaction. "The divestiture of VasoHealthcare IT will allow us to sharpen our focus on our core operations and competencies. We believe the sale of this line of business is a positive development for our shareholders and provides a strong future for the VasoHealthcare IT team as part of Nanox."

VasoHealthcare IT provides imaging information technology to hospitals and healthcare providers and represented less than 5% of Vaso's total revenue. The transaction consideration is up to $800,000, with $200,000 payable at closing and up to $600,000 as an earnout based on the post-closing performance of the business. Vaso expects to use the proceeds from the sale to invest in its other business lines and for strategic initiatives.

**Advisors**

Barley Snyder, LLP acted as legal counsel to Vaso Corporation.

**About Vaso**

*Vaso Corporation (OTCQX: VASO), headquartered in Plainview, New York, is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional sales service arm for GEHealthCare's diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managed connectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietary medical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.*

*For additional information, please visit www.vasocorporation.com or contact us at info@vasocorporation.*

*Forward Looking Statements. Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "optimistic", "plans", "potential", "looking forward", and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; failure to achieve any portion of the earnout; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.*

*# # #*